United Kingdom, June 07, 2018
EMJ 3.2 has entered the building! This truly multidisciplinary eJournal returns for its 10th issue and its second of 2018. EMJ 3.2 includes a plethora of high-quality peer-reviewed articles that detail a myriad of fascinating topics across seven therapeutic areas: urology, haematology, oncology, gastroenterology, hepatology, neurology, and reproductive health. This eJournal must not be missed.
Look After Your Liver
EMJ 3.2 proves to be a hub of hepatology research and includes three fascinating articles that focus on the body’s largest internal organ. Firstly, Arefyev et al. investigate the adverse effects of angiogenesis on the liver, carrying out a comprehensive review of the various techniques, technologies, and models available to researchers to uncover the adverse effects that this vital bodily function has on the organ. McCulloch and colleagues also provide an insightful review that will fascinate hepatologists and oncologists alike as they discuss the link between sarcopenia and visceral fat deposition and the development of hepatocellular carcinoma. Finally, a narrative review on the practical diagnosis and staging of nonalcoholic fatty liver disease is a timely contribution from Gallacher and McPherson as the obesity pandemic continues to spread across the globe. The authors provide an overview of nonalcoholic fatty liver disease diagnosis and staging procedures, which will be useful in the primary and secondary healthcare settings for management of a disease that is only growing in prevalence.
The Editor’s Pick for EMJ 3.2 comes from the gastroenterological sphere. “Pyruvate Kinase and Gastric Cancer: A Potential Marker”, penned by Macedo and colleagues, details the use of PKM2 and PDK1 in combination with CA72-4 during the diagnosis of gastric cancers. This research could open novel avenues, propelling cancer medicine into a new age.
Much, Much More
Oncologists are spoilt for choice in this edition. In addition to the aforementioned hepatic and gastroenterological insights, Yang and colleagues consider the developments in personalised care of multiple myeloma patients, while Vavalà debates the use of immunotherapy in lung cancer, specifically non-small cell lung cancer, which accounts for 85% of lung cancers. For those wishing to extend their knowledge even further, much more can be found within.
“With offerings from a range of therapeutic areas, from urology and haematology to hepatology and reproductive health, EMJ 3.2 has something fascinating on offer for everyone” commented Spencer Gore, CEO, European Medical Group. “The EMJ team are confident that hours of stimulating debate will be triggered, changing the face of therapeutics, research, and diagnostics.”
Notes to Editors
About the European Medical Journal
The European Medical Journal is an independent company that annually produces a collection of open-access medical eJournals covering therapeutic areas such as Respiratory, Gastroenterology, Cardiology, and Urology. By combining editorials from key opinion leaders with concise news coverage from the leading congresses within the medical industry, we aim to deliver first-class insight into ground-breaking changes and advances in medicine. The production of our high-quality, peer-reviewed eJournals, and our collaborations with independent clinical bodies result in a dynamic and contemporary tool with which to assist industry professionals across Europe in progressively developing their performance and efficacy.
Name: Stacey Rivers
Number: 01245 334452
E-mail: [email protected]